117
Participants
Start Date
May 24, 2022
Primary Completion Date
September 1, 2031
Study Completion Date
September 1, 2031
Venetoclax
"Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia."
RECRUITING
Department of Hematology, Rigshospitalet, Copenhagen
Helse Stavanger HF
OTHER_GOV
University Hospital of North Norway
OTHER
Haukeland University Hospital
OTHER
St. Olavs Hospital
OTHER
Vestre Viken Hospital Trust
OTHER
Helse Møre og Romsdal HF
OTHER_GOV
Karolinska University Hospital
OTHER
Skane University Hospital
OTHER
Uppsala University Hospital
OTHER
Helsinki University Central Hospital
OTHER
Oulu University Hospital
OTHER
Tampere University Hospital
OTHER
Kuopio University Hospital
OTHER
Rigshospitalet, Denmark
OTHER